ID   SPEG_HUMAN              Reviewed;        3267 AA.
AC   Q15772; A8K0G6; A8MRU0; Q27J74; Q695L1; Q6FGA6; Q6ZQW1; Q6ZTL8;
AC   Q9P2P9;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 4.
DT   12-APR-2017, entry version 162.
DE   RecName: Full=Striated muscle preferentially expressed protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Aortic preferentially expressed protein 1;
DE            Short=APEG-1;
GN   Name=SPEG; Synonyms=APEG1, KIAA1297;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=8663449; DOI=10.1074/jbc.271.29.17354;
RA   Hsieh C.-M., Yoshizumi M., Endege W.O., Kho C.-J., Jain M.K.,
RA   Kashiki S., de Los Santos R., Lee W.-S., Perrella M.A., Lee M.-E.;
RT   "APEG-1, a novel gene preferentially expressed in aortic smooth muscle
RT   cells, is down-regulated by vascular injury.";
RL   J. Biol. Chem. 271:17354-17359(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Cerebellum, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 12-129 (ISOFORM 1), AND ALTERNATIVE
RP   PROMOTER USAGE.
RX   PubMed=16545539; DOI=10.1016/j.ygeno.2006.01.009;
RA   Tam J.L.Y., Triantaphyllopoulos K., Todd H., Raguz S., de Wit T.,
RA   Morgan J.E., Partridge T.A., Makrinou E., Grosveld F., Antoniou M.;
RT   "The human desmin locus: gene organization and LCR-mediated
RT   transcriptional control.";
RL   Genomics 87:733-746(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 130-3267 (ISOFORM 1), TISSUE
RP   SPECIFICITY, AND VARIANT THR-2687.
RX   PubMed=15185077; DOI=10.1007/s00427-004-0413-5;
RA   Sutter S.B., Raeker M.O., Borisov A.B., Russell M.W.;
RT   "Orthologous relationship of obscurin and Unc-89: phylogeny of a novel
RT   family of tandem myosin light chain kinases.";
RL   Dev. Genes Evol. 214:352-359(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 982-3267 (ISOFORM 1), AND
RP   VARIANT THR-2687.
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI.
RT   The complete sequences of 150 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-488, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (0.96 ANGSTROMS) OF 864-962, AND SUBUNIT.
RX   PubMed=16354304; DOI=10.1186/1472-6807-5-21;
RA   Manjasetty B.A., Niesen F.H., Scheich C., Roske Y., Goetz F.,
RA   Behlke J., Sievert V., Heinemann U., Bussow K.;
RT   "X-ray structure of engineered human aortic preferentially expressed
RT   protein-1 (APEG-1).";
RL   BMC Struct. Biol. 5:21-21(2005).
RN   [12]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-206; CYS-934; GLN-966; LEU-1103;
RP   VAL-1135; ASP-1178; TRP-1234; GLN-1340; CYS-1621; TRP-1903; THR-2687;
RP   MET-2742 AND ARG-3079.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [13]
RP   INTERACTION WITH MTM1, INVOLVEMENT IN CNM5, AND VARIANT CNM5 VAL-2757.
RX   PubMed=25087613; DOI=10.1016/j.ajhg.2014.07.004;
RA   Agrawal P.B., Pierson C.R., Joshi M., Liu X., Ravenscroft G.,
RA   Moghadaszadeh B., Talabere T., Viola M., Swanson L.C., Haliloglu G.,
RA   Talim B., Yau K.S., Allcock R.J., Laing N.G., Perrella M.A.,
RA   Beggs A.H.;
RT   "SPEG interacts with myotubularin, and its deficiency causes
RT   centronuclear myopathy with dilated cardiomyopathy.";
RL   Am. J. Hum. Genet. 95:218-226(2014).
CC   -!- FUNCTION: Isoform 3 may have a role in regulating the growth and
CC       differentiation of arterial smooth muscle cells.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts with MTM1. Isoform 3 is found as a monomer or
CC       homodimer. {ECO:0000269|PubMed:16354304,
CC       ECO:0000269|PubMed:25087613}.
CC   -!- INTERACTION:
CC       Q99873:PRMT1; NbExp=3; IntAct=EBI-1384196, EBI-78738;
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=4;
CC       Name=4;
CC         IsoId=Q15772-5; Sequence=Displayed;
CC         Note=No experimental confirmation available.;
CC       Name=2;
CC         IsoId=Q15772-3; Sequence=VSP_018259, VSP_018261, VSP_018262;
CC         Note=No experimental confirmation available.;
CC       Name=3; Synonyms=APEG1;
CC         IsoId=Q15772-4; Sequence=VSP_018258, VSP_018261, VSP_018262;
CC         Note=Produced by alternative promoter usage.;
CC       Name=1; Synonyms=SPEG;
CC         IsoId=Q15772-1; Sequence=VSP_036071;
CC         Note=Produced by alternative splicing.;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is preferentially expressed in
CC       striated muscle. Non-kinase form such as isoform 3 is
CC       predominantly expressed in the aorta. Isoform 3 appears to be
CC       expressed only in highly differentiated ASMC in normal vessel
CC       walls and down-regulated in dedifferentiated ASMC in vivo. In
CC       response to vascular injuries ASMC dedifferentiate and change from
CC       a quiescent and contractile phenotype to a proliferative and
CC       synthetic phenotype. This proliferation of vascular smooth muscle
CC       cells is one of the most prominent features of atherosclerosis.
CC       {ECO:0000269|PubMed:15185077, ECO:0000269|PubMed:8663449}.
CC   -!- INDUCTION: Isoform 3 is quickly down-regulated in response to
CC       vascular injury, when ASMC cells change from a quiescent to a
CC       proliferative phenotype. {ECO:0000269|PubMed:8663449}.
CC   -!- PTM: May be autophosphorylated.
CC   -!- DISEASE: Myopathy, centronuclear, 5 (CNM5) [MIM:615959]: A form of
CC       centronuclear myopathy, a congenital muscle disorder characterized
CC       by progressive muscular weakness and wasting involving mainly limb
CC       girdle, trunk, and neck muscles. It may also affect distal
CC       muscles. Weakness may be present during childhood or adolescence
CC       or may not become evident until the third decade of life. Ptosis
CC       is a frequent clinical feature. The most prominent histopathologic
CC       features include high frequency of centrally located nuclei in
CC       muscle fibers not secondary to regeneration, radial arrangement of
CC       sarcoplasmic strands around the central nuclei, and predominance
CC       and hypotrophy of type 1 fibers. CNM5 features include severe
CC       neonatal hypotonia with respiratory insufficiency, difficulty
CC       feeding, and delayed motor development. Some patients die in
CC       infancy, and some develop dilated cardiomyopathy.
CC       {ECO:0000269|PubMed:25087613}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Expression is under the tight control of the locus
CC       control region (LCRs).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAY15052.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=ABD61734.1; Type=Frameshift; Positions=31, 35; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U57099; AAC50599.1; -; mRNA.
DR   EMBL; AK126500; BAC86568.1; -; mRNA.
DR   EMBL; AK289531; BAF82220.1; -; mRNA.
DR   EMBL; CR542201; CAG46998.1; -; mRNA.
DR   EMBL; AC053503; AAY15052.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471063; EAW70747.1; -; Genomic_DNA.
DR   EMBL; BC006346; AAH06346.1; -; mRNA.
DR   EMBL; DQ395348; ABD61734.1; ALT_FRAME; mRNA.
DR   EMBL; AY603755; AAT80901.1; -; mRNA.
DR   EMBL; AB037718; BAA92535.1; -; mRNA.
DR   CCDS; CCDS42824.1; -. [Q15772-5]
DR   CCDS; CCDS54432.1; -. [Q15772-4]
DR   RefSeq; NP_001166947.1; NM_001173476.1. [Q15772-4]
DR   RefSeq; NP_005867.3; NM_005876.4. [Q15772-5]
DR   RefSeq; XP_016858651.1; XM_017003162.1. [Q15772-3]
DR   UniGene; Hs.21639; -.
DR   PDB; 1U2H; X-ray; 0.96 A; A=864-960.
DR   PDBsum; 1U2H; -.
DR   ProteinModelPortal; Q15772; -.
DR   SMR; Q15772; -.
DR   BioGrid; 115579; 5.
DR   IntAct; Q15772; 5.
DR   STRING; 9606.ENSP00000311684; -.
DR   iPTMnet; Q15772; -.
DR   PhosphoSitePlus; Q15772; -.
DR   BioMuta; SPEG; -.
DR   DMDM; 218512143; -.
DR   EPD; Q15772; -.
DR   MaxQB; Q15772; -.
DR   PaxDb; Q15772; -.
DR   PeptideAtlas; Q15772; -.
DR   PRIDE; Q15772; -.
DR   DNASU; 10290; -.
DR   Ensembl; ENST00000312358; ENSP00000311684; ENSG00000072195. [Q15772-5]
DR   Ensembl; ENST00000396686; ENSP00000379917; ENSG00000072195. [Q15772-4]
DR   Ensembl; ENST00000396688; ENSP00000379919; ENSG00000072195. [Q15772-4]
DR   Ensembl; ENST00000396689; ENSP00000379920; ENSG00000072195. [Q15772-4]
DR   GeneID; 10290; -.
DR   KEGG; hsa:10290; -.
DR   UCSC; uc002vlq.4; human. [Q15772-5]
DR   CTD; 10290; -.
DR   DisGeNET; 10290; -.
DR   GeneCards; SPEG; -.
DR   H-InvDB; HIX0002864; -.
DR   HGNC; HGNC:16901; SPEG.
DR   HPA; HPA018904; -.
DR   MalaCards; SPEG; -.
DR   MIM; 615950; gene.
DR   MIM; 615959; phenotype.
DR   neXtProt; NX_Q15772; -.
DR   OpenTargets; ENSG00000072195; -.
DR   Orphanet; 169186; Autosomal recessive centronuclear myopathy.
DR   PharmGKB; PA142672598; -.
DR   eggNOG; KOG0032; Eukaryota.
DR   eggNOG; KOG0613; Eukaryota.
DR   eggNOG; ENOG410XQFD; LUCA.
DR   GeneTree; ENSGT00760000118877; -.
DR   HOVERGEN; HBG083339; -.
DR   InParanoid; Q15772; -.
DR   KO; K08809; -.
DR   OMA; QYRDVHR; -.
DR   OrthoDB; EOG091G002S; -.
DR   PhylomeDB; Q15772; -.
DR   TreeFam; TF331962; -.
DR   SignaLink; Q15772; -.
DR   ChiTaRS; SPEG; human.
DR   EvolutionaryTrace; Q15772; -.
DR   GeneWiki; SPEG; -.
DR   GenomeRNAi; 10290; -.
DR   PRO; PR:Q15772; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000072195; -.
DR   CleanEx; HS_SPEG; -.
DR   ExpressionAtlas; Q15772; baseline and differential.
DR   Genevisible; Q15772; HS.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0042692; P:muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0007517; P:muscle organ development; TAS:ProtInc.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; TAS:ProtInc.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.40.10; -; 12.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR015726; Ser/Thr_kin_striated-sp.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR10489:SF758; PTHR10489:SF758; 1.
DR   Pfam; PF07679; I-set; 9.
DR   Pfam; PF00069; Pkinase; 2.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00409; IG; 9.
DR   SMART; SM00408; IGc2; 9.
DR   SMART; SM00220; S_TKc; 2.
DR   SUPFAM; SSF48726; SSF48726; 9.
DR   SUPFAM; SSF49265; SSF49265; 2.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS50835; IG_LIKE; 8.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Alternative splicing;
KW   ATP-binding; Complete proteome; Differentiation; Disease mutation;
KW   Disulfide bond; Immunoglobulin domain; Kinase; Methylation;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN         1   3267       Striated muscle preferentially expressed
FT                                protein kinase.
FT                                /FTId=PRO_0000072666.
FT   DOMAIN       43    124       Ig-like 1.
FT   DOMAIN      722    810       Ig-like 2.
FT   DOMAIN      869    958       Ig-like 3.
FT   DOMAIN      963   1057       Ig-like 4.
FT   DOMAIN     1064   1152       Ig-like 5.
FT   DOMAIN     1188   1278       Ig-like 6.
FT   DOMAIN     1285   1382       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1384   1480       Ig-like 7.
FT   DOMAIN     1485   1573       Ig-like 8.
FT   DOMAIN     1601   1854       Protein kinase 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN     2583   2673       Ig-like 9.
FT   DOMAIN     2680   2774       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     2966   3218       Protein kinase 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1607   1615       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    2972   2980       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS    284    345       Pro-rich.
FT   COMPBIAS    525    634       Pro-rich.
FT   COMPBIAS   1919   1924       Poly-Ser.
FT   COMPBIAS   1925   1931       Poly-Glu.
FT   COMPBIAS   2175   2316       Pro-rich.
FT   COMPBIAS   2339   2503       Arg-rich.
FT   COMPBIAS   2786   2965       Pro-rich.
FT   ACT_SITE   1719   1719       Proton acceptor. {ECO:0000250}.
FT   ACT_SITE   3085   3085       Proton acceptor. {ECO:0000250}.
FT   BINDING    1630   1630       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING    2995   2995       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     139    139       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES     364    364       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES     371    371       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES     375    375       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES     378    378       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES     381    381       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES     419    419       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES     449    449       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES     453    453       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES     488    488       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     506    506       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES     526    526       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES     549    549       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES    1128   1128       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    1172   1172       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    1988   1988       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    2014   2014       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    2015   2015       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    2037   2037       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES    2055   2055       Asymmetric dimethylarginine; alternate.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    2055   2055       Omega-N-methylarginine; alternate.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    2109   2109       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES    2130   2130       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES    2139   2139       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    2177   2177       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES    2376   2376       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    2380   2380       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    2410   2410       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES    2414   2414       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES    2438   2438       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES    2439   2439       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    2444   2444       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    2448   2448       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    2521   2521       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    2524   2524       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    2559   2559       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES    2771   2771       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   MOD_RES    2774   2774       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63638}.
FT   MOD_RES    2949   2949       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62407}.
FT   DISULFID    989   1041       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID   2605   2657       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ       1    849       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8663449,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_018258.
FT   VAR_SEQ       1    792       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_018259.
FT   VAR_SEQ     961    962       AH -> GE (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8663449,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_018261.
FT   VAR_SEQ     963   3267       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8663449,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_018262.
FT   VAR_SEQ    3209   3267       LQDCLAHPWLQDAYLMKLRRQTLTFTTNRLKEFLGEQRRRR
FT                                AEAATRHKVLLRSYPGGP -> SCLSVCHKEIKMASS (in
FT                                isoform 1). {ECO:0000303|PubMed:10718198,
FT                                ECO:0000303|PubMed:15185077,
FT                                ECO:0000303|PubMed:16545539}.
FT                                /FTId=VSP_036071.
FT   VARIANT     206    206       R -> H (in dbSNP:rs55821435).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041101.
FT   VARIANT     934    934       R -> C (in dbSNP:rs34398769).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041102.
FT   VARIANT     966    966       R -> Q (in dbSNP:rs34861443).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041103.
FT   VARIANT    1103   1103       P -> L (in dbSNP:rs56334571).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041104.
FT   VARIANT    1135   1135       A -> V (in dbSNP:rs55670811).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041105.
FT   VARIANT    1178   1178       E -> D (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041106.
FT   VARIANT    1234   1234       R -> W (in dbSNP:rs55916864).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041107.
FT   VARIANT    1340   1340       R -> Q (in dbSNP:rs34994343).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041108.
FT   VARIANT    1621   1621       R -> C (in dbSNP:rs55646900).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041109.
FT   VARIANT    1903   1903       R -> W (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs762000831).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041110.
FT   VARIANT    2189   2189       P -> L (in dbSNP:rs10755037).
FT                                /FTId=VAR_059769.
FT   VARIANT    2687   2687       P -> T (in dbSNP:rs13026308).
FT                                {ECO:0000269|PubMed:10718198,
FT                                ECO:0000269|PubMed:15185077,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041111.
FT   VARIANT    2742   2742       V -> M (in a gastric adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs566841339).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041112.
FT   VARIANT    2757   2757       G -> V (in CNM5; dbSNP:rs587777676).
FT                                {ECO:0000269|PubMed:25087613}.
FT                                /FTId=VAR_071808.
FT   VARIANT    3079   3079       H -> R (in dbSNP:rs12464085).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041113.
FT   CONFLICT     71     71       Q -> H (in Ref. 7; ABD61734).
FT                                {ECO:0000305}.
FT   CONFLICT     73     73       S -> I (in Ref. 7; ABD61734).
FT                                {ECO:0000305}.
FT   CONFLICT   2047   2047       S -> G (in Ref. 8; AAT80901 and 9;
FT                                BAA92535). {ECO:0000305}.
FT   CONFLICT   3005   3005       R -> P (in Ref. 8; AAT80901 and 9;
FT                                BAA92535). {ECO:0000305}.
FT   STRAND      867    873       {ECO:0000244|PDB:1U2H}.
FT   STRAND      878    881       {ECO:0000244|PDB:1U2H}.
FT   STRAND      886    896       {ECO:0000244|PDB:1U2H}.
FT   STRAND      899    904       {ECO:0000244|PDB:1U2H}.
FT   STRAND      915    919       {ECO:0000244|PDB:1U2H}.
FT   HELIX       921    923       {ECO:0000244|PDB:1U2H}.
FT   STRAND      924    931       {ECO:0000244|PDB:1U2H}.
FT   HELIX       934    936       {ECO:0000244|PDB:1U2H}.
FT   STRAND      938    946       {ECO:0000244|PDB:1U2H}.
FT   STRAND      949    960       {ECO:0000244|PDB:1U2H}.
SQ   SEQUENCE   3267 AA;  354289 MW;  E67BEB5624144233 CRC64;
     MQKARGTRGE DAGTRAPPSP GVPPKRAKVG AGGGAPVAVA GAPVFLRPLK NAAVCAGSDV
     RLRVVVSGTP QPSLRWFRDG QLLPAPAPEP SCLWLRRCGA QDAGVYSCMA QNERGRASCE
     AVLTVLEVGD SETAEDDISD VQGTQRLELR DDGAFSTPTG GSDTLVGTSL DTPPTSVTGT
     SEEQVSWWGS GQTVLEQEAG SGGGTRRLPG SPRQAQATGA GPRHLGVEPL VRASRANLVG
     ASWGSEDSLS VASDLYGSAF SLYRGRALSI HVSVPQSGLR REEPDLQPQL ASEAPRRPAQ
     PPPSKSALLP PPSPRVGKRS PPGPPAQPAA TPTSPHRRTQ EPVLPEDTTT EEKRGKKSKS
     SGPSLAGTAE SRPQTPLSEA SGRLSALGRS PRLVRAGSRI LDKLQFFEER RRSLERSDSP
     PAPLRPWVPL RKARSLEQPK SERGAPWGTP GASQEELRAP GSVAERRRLF QQKAASLDER
     TRQRSPASDL ELRFAQELGR IRRSTSREEL VRSHESLRAT LQRAPSPREP GEPPLFSRPS
     TPKTSRAVSP AAAQPPSPSS AEKPGDEPGR PRSRGPAGRT EPGEGPQQEV RRRDQFPLTR
     SRAIQECRSP VPPPAADPPE ARTKAPPGRK REPPAQAVRF LPWATPGLEG AAVPQTLEKN
     RAGPEAEKRL RRGPEEDGPW GPWDRRGARS QGKGRRARPT SPELESSDDS YVSAGEEPLE
     APVFEIPLQN VVVAPGADVL LKCIITANPP PQVSWHKDGS ALRSEGRLLL RAEGERHTLL
     LREARAADAG SYMATATNEL GQATCAASLT VRPGGSTSPF SSPITSDEEY LSPPEEFPEP
     GETWPRTPTM KPSPSQNRRS SDTGSKAPPT FKVSLMDQSV REGQDVIMSI RVQGEPKPVV
     SWLRNRQPVR PDQRRFAEEA EGGLCRLRIL AAERGDAGFY TCKAVNEYGA RQCEARLEVR
     AHPESRSLAV LAPLQDVDVG AGEMALFECL VAGPTDVEVD WLCRGRLLQP ALLKCKMHFD
     GRKCKLLLTS VHEDDSGVYT CKLSTAKDEL TCSARLTVRP SLAPLFTRLL EDVEVLEGRA
     ARFDCKISGT PPPVVTWTHF GCPMEESENL RLRQDGGLHS LHIAHVGSED EGLYAVSAVN
     THGQAHCSAQ LYVEEPRTAA SGPSSKLEKM PSIPEEPEQG ELERLSIPDF LRPLQDLEVG
     LAKEAMLECQ VTGLPYPTIS WFHNGHRIQS SDDRRMTQYR DVHRLVFPAV GPQHAGVYKS
     VIANKLGKAA CYAHLYVTDV VPGPPDGAPQ VVAVTGRMVT LTWNPPRSLD MAIDPDSLTY
     TVQHQVLGSD QWTALVTGLR EPGWAATGLR KGVQHIFRVL STTVKSSSKP SPPSEPVQLL
     EHGPTLEEAP AMLDKPDIVY VVEGQPASVT VTFNHVEAQV VWRSCRGALL EARAGVYELS
     QPDDDQYCLR ICRVSRRDMG ALTCTARNRH GTQTCSVTLE LAEAPRFESI MEDVEVGAGE
     TARFAVVVEG KPLPDIMWYK DEVLLTESSH VSFVYEENEC SLVVLSTGAQ DGGVYTCTAQ
     NLAGEVSCKA ELAVHSAQTA MEVEGVGEDE DHRGRRLSDF YDIHQEIGRG AFSYLRRIVE
     RSSGLEFAAK FIPSQAKPKA SARREARLLA RLQHDCVLYF HEAFERRRGL VIVTELCTEE
     LLERIARKPT VCESEIRAYM RQVLEGIHYL HQSHVLHLDV KPENLLVWDG AAGEQQVRIC
     DFGNAQELTP GEPQYCQYGT PEFVAPEIVN QSPVSGVTDI WPVGVVAFLC LTGISPFVGE
     NDRTTLMNIR NYNVAFEETT FLSLSREARG FLIKVLVQDR LRPTAEETLE HPWFKTQAKG
     AEVSTDHLKL FLSRRRWQRS QISYKCHLVL RPIPELLRAP PERVWVTMPR RPPPSGGLSS
     SSDSEEEELE ELPSVPRPLQ PEFSGSRVSL TDIPTEDEAL GTPETGAATP MDWQEQGRAP
     SQDQEAPSPE ALPSPGQEPA AGASPRRGEL RRGSSAESAL PRAGPRELGR GLHKAASVEL
     PQRRSPSPGA TRLARGGLGE GEYAQRLQAL RQRLLRGGPE DGKVSGLRGP LLESLGGRAR
     DPRMARAASS EAAPHHQPPL ENRGLQKSSS FSQGEAEPRG RHRRAGAPLE IPVARLGARR
     LQESPSLSAL SEAQPSSPAR PSAPKPSTPK SAEPSATTPS DAPQPPAPQP AQDKAPEPRP
     EPVRASKPAP PPQALQTLAL PLTPYAQIIQ SLQLSGHAQG PSQGPAAPPS EPKPHAAVFA
     RVASPPPGAP EKRVPSAGGP PVLAEKARVP TVPPRPGSSL SSSIENLESE AVFEAKFKRS
     RESPLSLGLR LLSRSRSEER GPFRGAEEED GIYRPSPAGT PLELVRRPER SRSVQDLRAV
     GEPGLVRRLS LSLSQRLRRT PPAQRHPAWE ARGGDGESSE GGSSARGSPV LAMRRRLSFT
     LERLSSRLQR SGSSEDSGGA SGRSTPLFGR LRRATSEGES LRRLGLPHNQ LAAQAGATTP
     SAESLGSEAS ATSGSSAPGE SRSRLRWGFS RPRKDKGLSP PNLSASVQEE LGHQYVRSES
     DFPPVFHIKL KDQVLLEGEA ATLLCLPAAC PAPHISWMKD KKSLRSEPSV IIVSCKDGRQ
     LLSIPRAGKR HAGLYECSAT NVLGSITSSC TVAVARVPGK LAPPEVPQTY QDTALVLWKP
     GDSRAPCTYT LERRVDGESV WHPVSSGIPD CYYNVTHLPV GVTVRFRVAC ANRAGQGPFS
     NSSEKVFVRG TQDSSAVPSA AHQEAPVTSR PARARPPDSP TSLAPPLAPA APTPPSVTVS
     PSSPPTPPSQ ALSSLKAVGP PPQTPPRRHR GLQAARPAEP TLPSTHVTPS EPKPFVLDTG
     TPIPASTPQG VKPVSSSTPV YVVTSFVSAP PAPEPPAPEP PPEPTKVTVQ SLSPAKEVVS
     SPGSSPRSSP RPEGTTLRQG PPQKPYTFLE EKARGRFGVV RACRENATGR TFVAKIVPYA
     AEGKRRVLQE YEVLRTLHHE RIMSLHEAYI TPRYLVLIAE SCGNRELLCG LSDRFRYSED
     DVATYMVQLL QGLDYLHGHH VLHLDIKPDN LLLAPDNALK IVDFGSAQPY NPQALRPLGH
     RTGTLEFMAP EMVKGEPIGS ATDIWGAGVL TYIMLSGRSP FYEPDPQETE ARIVGGRFDA
     FQLYPNTSQS ATLFLRKVLS VHPWSRPSLQ DCLAHPWLQD AYLMKLRRQT LTFTTNRLKE
     FLGEQRRRRA EAATRHKVLL RSYPGGP
//
